anti cd33 monoclonal antibody bi 836858

Drug Overview

The medication known as anti cd33 monoclonal antibody bi 836858 is an investigational, humanized monoclonal antibody designed for the treatment of myeloid malignancies, specifically Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). It is a highly engineered immunotherapy that targets the CD33 antigen, a surface protein expressed on the vast majority of myeloid leukemia cells.

Developed by Boehringer Ingelheim, BI 836858 is distinguished by its “Fc-engineering.” Using specialized technology, the tail end of the antibody (the Fc region) has been modified to significantly increase its affinity for the receptors on Natural Killer (NK) cells. This makes BI 836858 a more potent recruiter of the body’s innate immune system compared to standard, non-engineered antibodies.

• Generic Name: BI 836858.
• Drug Class: Humanized, Fc-engineered Monoclonal Antibody (IgG1).
• Target: CD33 (Sialic acid-binding Ig-like lectin 3).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, BI 836858 is not FDA-approved. It has been evaluated in Phase I/II clinical trials (e.g., NCT02632721 and NCT03013998). While clinical development by the original manufacturer was paused in some regions to pivot toward combination therapies, it remains a critical agent of study in the leukemia research community.

What Is It and How Does It Work? (Mechanism of Action)

The CD33 Target

CD33 is a hallmark protein of the myeloid lineage. It is found on approximately 90% of AML blasts and on the Leukemic Stem Cells (LSCs) that drive disease recurrence. Because CD33 is not found on the most primitive blood-forming stem cells, it is an ideal “biological flag” for targeted therapy.

Molecular Level Mechanisms

1. Selective Binding: After infusion, BI 836858 circulates and binds specifically to the CD33 receptor on the surface of the leukemia cell.
2. Fc-Engineered Recruitment: The antibody’s Fc region has been modified (specifically by changing the sugar structure or amino acid sequence) to bind more tightly to CD16 (Fc\gammaRIIIa) receptors on NK cells.
3. Natural Killer Cell Activation: This tight binding sends a strong activation signal to the NK cell, which then locks onto the leukemia cell.
4. Lytic De-granulation: The NK cell releases toxic granules containing perforins and granzymes. Perforins create holes in the leukemia cell membrane, while granzymes enter to trigger apoptosis (programmed cell death).
5. Macrophage Involvement: The antibody also facilitates Antibody-Dependent Cellular Phagocytosis (ADCP), where macrophages (the body’s “clean-up” cells) recognize the antibody-coated cancer cell and engulf it.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for BI 836858.

It is strictly available through participation in clinical trials. It has been primarily investigated for:

• Relapsed or Refractory Acute Myeloid Leukemia (AML): For patients who have failed standard intensive chemotherapy.
• Myelodysplastic Syndromes (MDS): Investigated for patients with high-risk MDS who have not responded to hypomethylating agents (like Azacitidine).
• Post-Stem Cell Transplant Maintenance: Studied as a way to prevent relapse by clearing “minimal residual disease” after a transplant.

Dosage and Administration Protocols

In clinical research, BI 836858 is typically administered as an outpatient infusion, though the first dose may require longer observation.

Clinical Efficacy and Research Results

As of 2024–2026 data updates, BI 836858 has demonstrated the following clinical trends:

• NK Cell Activation: Pharmacodynamic studies confirmed that the drug successfully increases NK cell activity in the bone marrow of AML patients.
• Safety Milestones: Compared to CD33-targeting drugs that carry toxins (like Mylotarg), BI 836858 has shown a lower rate of Veno-Occlusive Disease (VOD), a dangerous liver condition.
• Blast Reduction: While single-agent activity in refractory patients was modest, the drug showed significant “synergy” when combined with other agents, leading to deeper reductions in bone marrow blasts.
• Resistance Bypass: Its Fc-engineered design allows it to work in patients whose NK cells might have genetic variations (polymorphisms) that make them less responsive to traditional antibodies.

Safety Profile and Side Effects

Because BI 836858 activates the immune system, the side effects are primarily related to “infusion reactions” and the impact on normal blood counts.

Common Side Effects (>20%):

• Infusion-Related Reactions (IRR): Fever, chills, and rigors (shaking) during or shortly after the IV. This is typically managed with pre-medication.
• Fatigue: A general sense of tiredness.
• Nausea: Usually mild and well-controlled.
• Pyrexia: Temporary fever in the 24 hours following the dose.

Serious Adverse Events:

• Myelosuppression: A drop in white blood cell and platelet counts. This is common because the drug may impact some healthy CD33-positive myeloid cells.
• Infections: Increased risk of infection due to low neutrophil counts.
• Hepatotoxicity: Mild to moderate elevations in liver enzymes, requiring regular blood monitoring.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, BI 836858 is being studied for “Post-Transplant Immune Reconstruction.” After a bone marrow transplant, the new immune system (the “graft”) is often slow to find and kill remaining cancer cells. Researchers are testing whether BI 836858 can act as a “guide” for the new NK cells, helping them identify and eliminate any surviving leukemia stem cells to ensure the transplant leads to a permanent cure.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• CD33 Expression Confirmation: A bone marrow flow cytometry test is necessary to ensure the cancer cells possess the CD33 target.
• Baseline CBC with Differential: To track blood counts before and after treatment.
• Liver Function Tests (LFTs): To establish a baseline for hepatic health.

Precautions:

• Pre-medication Compliance: Patients are typically given acetaminophen and an antihistamine (like Diphenhydramine) before each dose to prevent infusion reactions.
• Infection Monitoring: Report any fever over 100.4°F (38°C) immediately.

“Do’s and Don’ts” List:

• DO report any “shaking chills” or itching during the infusion to your nurse immediately.
• DO stay well-hydrated to help your body process the fragments of dead leukemia cells.
• DON’T ignore minor bruising or small red spots on the skin (petechiae), as these can indicate low platelets.
• DON’T start any new herbal supplements without consulting your oncologist, as they may interfere with the drug’s immune-modulating effects.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. BI 836858 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for any indication. It is available only through participation in approved clinical trials. Always consult with a qualified hematologist-oncologist regarding currently available and approved treatments or your eligibility for research studies.